Albuterol sulfate mechanism of action
Pro Research Analysisby 
Searched over 200M research papers
Albuterol Sulfate Mechanism of Action
Introduction to Albuterol Sulfate
Albuterol sulfate, also known as salbutamol sulfate, is a widely used medication for the treatment of bronchospasm in conditions such as asthma and chronic obstructive pulmonary disease (COPD). It is a selective beta-2 adrenergic receptor agonist, which means it specifically targets beta-2 receptors in the lungs to produce its therapeutic effects.
Beta-2 Adrenergic Receptor Agonism
Albuterol sulfate works by stimulating beta-2 adrenergic receptors located on the smooth muscle cells of the airways. When these receptors are activated, they trigger a cascade of intracellular events that lead to the relaxation of bronchial smooth muscle. This relaxation results in the widening of the airways (bronchodilation), making it easier for patients to breathe1 3 9.
Mechanism of Bronchodilation
The activation of beta-2 receptors by albuterol leads to the activation of adenylate cyclase, an enzyme that converts ATP to cyclic AMP (cAMP). Increased levels of cAMP result in the activation of protein kinase A (PKA), which then phosphorylates various target proteins. This phosphorylation process reduces intracellular calcium concentrations and inhibits myosin light-chain kinase, ultimately leading to smooth muscle relaxation and bronchodilation1 3 9.
Pharmacokinetics and Bioavailability
Albuterol sulfate is available in various formulations, including inhalers, tablets, and syrups. The drug is rapidly absorbed, with peak plasma concentrations typically reached within 1.8 to 2 hours after oral administration. The bioavailability of albuterol from tablet formulations is equivalent to that from a solution, ensuring consistent therapeutic effects across different delivery methods6.
Stereoselective Sulfation
Albuterol exists as two enantiomers, (-)-albuterol and (+)-albuterol. Studies have shown that the sulfation process in the liver preferentially targets the pharmacologically active (-)-enantiomer. This stereoselective sulfation results in higher bioavailability and efficacy of the active form of the drug, enhancing its therapeutic effects2.
Clinical Efficacy and Safety
Albuterol sulfate has been demonstrated to be effective in various clinical settings. For instance, it has been shown to protect against exercise-induced bronchospasm more effectively than metaproterenol sulfate, with a longer duration of action1. Additionally, extended-release formulations of albuterol have been found to improve pulmonary function and reduce asthma symptoms in children3. The drug is generally well-tolerated, with a safety profile comparable to other bronchodilators such as epinephrine5.
Conclusion
Albuterol sulfate is a potent and selective beta-2 adrenergic receptor agonist that effectively induces bronchodilation by relaxing bronchial smooth muscle. Its rapid absorption and stereoselective sulfation contribute to its high efficacy and bioavailability. Clinical studies have consistently demonstrated its effectiveness in managing bronchospasm and improving respiratory function, making it a cornerstone in the treatment of asthma and other obstructive airway diseases.
Sources and full results
Most relevant research papers on this topic
Albuterol protects against exercise-induced asthma longer than metaproterenol sulfate.
Albuterol has a longer duration of action in preventing exercise-induced asthma than metaproterenol sulfate, but both medications are equally effective in preventing exercise-induced bronchospasm in asthmatic children.
RCTStereoselective sulfation of albuterol in humans. Biosynthesis of the sulfate conjugate by HEP G2 cells.
The human hepatoma cell line Hep G2 efficiently synthesizes the sulfate conjugate of albuterol, with a preference for the sulfation of (-)-albuterol, potentially leading to higher bioavailability of (+)-albuterol in oral
In Vitro StudyExtended-release albuterol in the treatment of 6- to 12-year-old asthmatic children.
Extended-release albuterol tablets (4 mg) effectively improved pulmonary function and asthmatic symptoms in children aged 6-12 years, with no serious treatment-related adverse events.
RCTA randomized clinical trial of nebulized magnesium sulfate in addition to albuterol in the treatment of acute mild-to-moderate asthma exacerbations in adults.
Nebulized magnesium sulfate and albuterol provide no additional benefit for adult patients with mild-to-moderate asthma exacerbations, and their efficacy in severe asthma exacerbations remains unknown.
RCT
Highly CitedEfficacy of parenteral albuterol in the treatment of asthma. Comparison of its metabolic side effects with subcutaneous epinephrine.
Parenteral albuterol effectively improves asthma symptoms, with similar effects on serum potassium levels as subcutaneous epinephrine, potentially impacting clinical outcomes.
RCTComparative bioavailability and pharmacokinetics of three formulations of albuterol.
The bioavailability of albuterol from tablet and solution formulations is equivalent, with rapid absorption and comparable maximum drug concentrations.
RCTCumulative dose response study comparing HFA-134a albuterol sulfate and conventional CFC albuterol in patients with asthma.
HFA-134a albuterol sulfate provides bronchodilation comparable to CFC albuterol and has a similar safety profile in patients with asthma.
RCTEffect of Albuterol Premedication vs Placebo on the Occurrence of Respiratory Adverse Events in Children Undergoing Tonsillectomies: The REACT Randomized Clinical Trial.
Albuterol premedication significantly reduces the risk of perioperative respiratory adverse events in children undergoing tonsillectomy compared to placebo.
RCT
Large Human TrialHighly CitedComparative efficacy and safety of albuterol sulfate Spiros inhaler and albuterol metered-dose inhaler in asthma.
The Spiros dry powder inhaler and albuterol metered-dose inhaler are both well-tolerated and effective in treating moderate asthma patients.
RCTAerosolized albuterol sulfate used as a bronchodilator in horses with recurrent airway obstruction.
Aerosolized albuterol, 360 or 720 microg, is a safe and effective bronchodilator in horses with recurrent airway obstruction, providing rapid (5 minutes) relief for up to 3 hours.
Non-RCT
Animal StudyHighly Cited